TREATING

central sleep apnea

Press Releases

Respicardia Announces First U.S. Commercial Case With The remedē® System

Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch

Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first U.S. commercial case using the remedē® System to treat central sleep apnea …

Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea

Company announces strategic relationship with ZOLL Medical

Respicardia, Inc., a private medical technology company, announced today that the company has closed a $58.5 million financing, led by ZOLL Medical Corporation, a leading manufacturer of medical devices and related software solutions. All of Respicardia’s existing major investors helped to complete the financing round …

Respicardia’s remedē® System Receives FDA Approval

Breakthrough Treatment of Moderate to Severe Central Sleep Apnea in Adult Patients Now Available

Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its remedē® System, a transvenous implantable neurostimulation system that stimulates the phrenic nerve, and engages the diaphragm to restore natural breathing during sleep in patients with central sleep apnea …

MEDIA KIT

This content is password protected. To view media kit contents please enter your password below:

  • This field is for validation purposes and should be left unchanged.

For media inquiries please contact +1-952-540-4470

Am I a candidate
for remedē®?